Images List Premium Download Classic

Rheumatoid Arthritis

Rheumatoid Arthritis-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Novel anti-cd38 antibodies for the treatment of cancer
Sanofi
November 30, 2017 - N°20170343550

Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to cd38, are capable of killing cd3830 cells by apoptosis, antibody-dependent cell-mediated cytotoxicity (adcc), and/or complement-dependent cytotoxicity (cdc). Said antibodies and fragments thereof may be used in the treatment of tumors that express cd38 protein, such as multiple myeloma, chronic ...
Anti-ngf antibodies and methods using same
Rinat Neuroscience Corp.
November 30, 2017 - N°20170342143

The invention concerns anti-ngf antibodies (such as anti-ngf antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain.
Monoclonal antibody against muramyl peptides in prevention and treatment of immune-mediated diseases
Agency For Science, Technology And Research
November 30, 2017 - N°20170342136

Disclosed are methods of treating an autoimmune or inflammatory disease using a composition comprising an isolated antibody or an antigen-binding fragment or variant thereof that is capable of binding to muramyl peptide, derivative, analog or salt thereof, wherein said muramyl peptide comprises muramic acid and an amino acid selected from the group consisting of alanine, isoglutamine, glutamic acid and a ...
Rheumatoid Arthritis Patent Pack
Download 109+ patent application PDFs
Rheumatoid Arthritis Patent Applications
Download 109+ Rheumatoid Arthritis-related PDFs
For professional research & prior art discovery
inventor
  • 109+ full patent PDF documents of Rheumatoid Arthritis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Rheumatoid arthritis marker
Glycobiomarker Leading Innovation Co. Ltd.
November 23, 2017 - N°20170336413

A method of evaluating disease activity of rheumatoid arthritis with good sensitivity by a simple method, and a kit for use in the method. It provides a jacalin-binding o-linked oligosaccharide epitope as a negative marker for diagnosing rheumatoid arthritis, and enables more accurate assessment of disease condition by more objectively determining disease activity of rheumatoid arthritis using the amount of ...
Method to predict the lack of response to anti-tnf alpha therapies
Hospital Clinic De Barcelona
November 23, 2017 - N°20170335367

This invention provides methods for predicting response to anti-tnfα biological agent treatment in a rheumatoid arthritis patient and methods for selecting a treatment for a rheumatoid arthritis patient, the methods comprising determining the level of expression of pik3cd as a biomarker, and optionally also determining the level of expression of cx3cl1 as a second biomarker. The ...
Inhibitory oligonucleotide and use thereof
Sbi Biotech Co., Ltd.
November 23, 2017 - N°20170335325

The inhibitory oligonucleotides (odns) strongly block nf-κb activation induced by tlr9 agonists and tlr7 agonists. The production of proinflammatory cytokines, such as interleukin-6 and tumor necrosis factor alpha, is inhibited by the inhibitory-odns. Interferon production from human pbmc induced by tlr9 agonist is prevented by the inhibitory-odns. These odns can be used as a remedy for the ...
Rheumatoid Arthritis Patent Pack
Download 109+ patent application PDFs
Rheumatoid Arthritis Patent Applications
Download 109+ Rheumatoid Arthritis-related PDFs
For professional research & prior art discovery
inventor
  • 109+ full patent PDF documents of Rheumatoid Arthritis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Protease inhibitors
Biotheryx, Inc.
November 23, 2017 - N°20170334867

Or a pharmaceutically acceptable salt, n-oxide or hydrate thereof, have utility in the treatment of disorders characterized by inappropriate expression or activation of cathepsin k, such as osteoporosis, osteoarthritis, rheumatoid arthritis or bone metastases.
Chimeric compounds targeting proteins, compositions, methods, and uses thereof
Biotheryx, Inc.
November 23, 2017 - N°20170333443

The present invention provides chimeric compounds that modulate protein function, to restore protein homeostasis, including cytokine, aiolos, and/or ikaros activity, tnf-alpha activity, ck1-alpha activity and cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions, including in combination with other cytokine and inflammatory mediators, are provided. Methods of treatment, ...
Methods of predicting response to treatment with anti-tnfalpha biological inhibitors
Fundacio Hospital Universitari Vall D'hebron- Institut De Recerca
November 16, 2017 - N°20170328897

Provided herein are methods for predicting a response to anti-tnfα biologic treatment in patients suffering from rheumatoid arthritis (ra). The methods can be used to discriminate or categorize patients as likely to respond to a monoclonal antibody-based anti-tnfα biological inhibitor, but not likely to respond to an antibody fragment-based anti-tnfα biological inhibitor or a ...
Novel angiopoietin 2, vegf dual antagonists
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
November 16, 2017 - N°20170327569

The present disclosure relates to chimeric molecules which are fusion proteins comprising two components: an ang-2 binding peptide linked to either a vegf antibody or a vegf receptor-fc fusion protein. The ang2 peptide, vegf antibody, and vegf receptor-fc fusion proteins are each defined below with reference to percent identity to a reference sequence. The chimeric molecule is a fusion protein, ...
Substituted 6-aza-isoindolin-1-one derivatives
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
November 16, 2017 - N°20170327497

And pharmaceutically acceptable salts thereof, wherein g, p, r1, r2, r3a, r4, and r5 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of formula 1, to pharmaceutical compositions which contain them, and to their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, cancer, and ...
New molecules for bone tissue regeneration
Universita' Di Pisa
November 09, 2017 - N°20170319605

The invention relates to compounds of general formula (i) and pharmaceutically acceptable salts thereof: (i) wherein ri is selected from an scn— group or is an rconh— group; in particular, where ri=rconh, r is selected from an aromatic benzene ring substituted with an scn— group in the ortho, meta or para position, according to the following ...
Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase ...
Rhizen Pharmaceuticals Sa
November 09, 2017 - N°20170319558

This present invention relates to a method of treating a autoimmune, respiratory and/or inflammatory disease or condition (e. G., psoriasis, rheumatoid arthritis, asthma, copd). The method comprises administering a pi3k delta inhibitor or a dual pi3k delta-gamma inhibitor and a pde4 inhibitor. The present invention also relates to pharmaceutical compositions containing a pi3k delta or dual ...
Rheumatoid Arthritis Patent Pack
Download 109+ patent application PDFs
Rheumatoid Arthritis Patent Applications
Download 109+ Rheumatoid Arthritis-related PDFs
For professional research & prior art discovery
inventor
  • 109+ full patent PDF documents of Rheumatoid Arthritis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
6-aminopyridin-3-yl thiazoles as modulators of roryt
Rhizen Pharmaceuticals Sa
November 02, 2017 - N°20170313691

The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating rorγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of formula i.
Methods and compositions for the treatment of degenerate bone
Rhizen Pharmaceuticals Sa
November 02, 2017 - N°20170312385

The present disclosure relates to methods and compositions for the treatment of degenerate bone in a patient. In some embodiments, the methods and compositions disclosed herein are useful in the treatment, prevention, or in delaying the progression of a bone disease linked to bone degeneration, such as osteoarthritis (“oa”), rheumatoid arthritis, and avascular necrosis.
Treatment methods for rheumatoid arthritis
Rhizen Pharmaceuticals Sa
October 26, 2017 - N°20170304440

The present invention provides methods for selecting treatment methods for rheumatoid arthritis based on an objective selection process (algorithm). The present invention also provides methods for treating rheumatoid arthritis with treatment methods selected based on the algorithm disclosed herein. The methods of the present invention provide a more effective means for treating patients with rheumatoid arthritis.
Treatment of rheumatoid arthritis
Seven To Stand, Inc.
October 26, 2017 - N°20170304325

A composition for treating chronic inflammation, including an antibiotic, a lipophilic potentiating agent, a guanosine analog antiviral agent, and vitamin d in synergistically effective amounts. A method of treating chronic inflammation, by administering a synergistically effective amount of a composition including an antibiotic, a lipophilic potentiating agent, a guanosine analog antiviral agent, and vitamin d to an individual suffering from ...
Site directed mutagenesis of trem-1 antibodies for decreasing viscosity
Seven To Stand, Inc.
October 19, 2017 - N°20170298130

Antibodies that are capable of specifically binding and preventing the activation of trem-1, a protein expressed on monocytes, macrophages and neutrophils with both good affinity and low viscosity at clinically relevant concentrations are described. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
Antigen associated with rheumatoid arthritis
Seven To Stand, Inc.
October 19, 2017 - N°20170298122

The invention relates to a binding member that binds the extra domain-a (ed-a) isoform of fibronectin for the detection and treatment of rheumatoid arthritis.
Modulators of ror-gamma receptors, composition and use thereof
Seven To Stand, Inc.
October 19, 2017 - N°20170298090

The present invention provides novel methods to treat disease by modulating retinoid-related orphan receptor gamma (ror-gamma) in vitro and in vivo with ursolic acid analogs, and compositions thereof. The methods and compounds disclosed herein are useful for inhibiting the differentiation of a population of t cells, or treating a disease related to th17 cell responses in a subject. Examples of ...
Antibodies specific for il-17a fused to hyaluronan binding peptide tags
Novartis Ag
October 12, 2017 - N°20170291939

The present disclosure relates to antibodies and proteins comprising an antigen-binding portion thereof that specifically bind to the pro-inflammatory cytokine il-17a and a peptide tag that binds hyaluronan (ha). The disclosure more specifically relates to specific antibodies and proteins that are il-17a antagonists (inhibit the activities of il-17a and il-17af) and are capable of inhibiting il-17...
Loading